|

Oxaliplatin injection Clinical Trials

3 actively recruiting trials

Also known as: NSC 266046

Pipeline

Phase 3: 3

Top Sponsors

  • Suzhou Suncadia Biopharmaceuticals Co., Ltd.1
  • Fujian Cancer Hospital1
  • BeBetter Med Inc1

Indications

  • Cancer3
  • Relapsed/Refractory Diffuse Large B-cell Lymphoma1
  • Diffuse Large B-Cell Lymphoma1
  • Gastric Cancer1

Other3 trials

A Phase 3 Clinical Study of SHR-A1912 Combined With R-GemOx Versus R-GemOx in Diffuse Large B-cell Lymphoma
Phase 3
Study Comparing BEBT-908 Combined With R to SOC for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Phase 3
Tislelizumab Plus FOLFOX Versus POF in the Treatment of Locally Advanced: a Multicenter, Open-label, Randomized Phase III Studyunresectable or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma
Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.